Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HASHARAM: residual thyroid capacity and gut microbiome in Hashimoto-related subclinical hypothyroidism
NL-OMON22728Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of thyrotropin alfa, metronidazole, ciprofloxacin and vancomycin in hypothyroidism and Hashimoto's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Residual thyroid secretion capacity after Thyrogen stimulation. Started Oct 2020; status: recruiting.
02
Drugs
thyrotropin alfametronidazoleciprofloxacinvancomycin
03
Conditions
hypothyroidismHashimoto's disease
Beyond the preview
Go deeper on NL-OMON22728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22728.